SAB BIOTHERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SAB BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $2.21M.
- SAB BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $7.24M.
- SAB BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $1.15K.
- SAB BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2020 was $9.90M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $2.21M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $7.24M 10-Q · filed 2026-08-06 | |
| 2021-03-31 | $1.15K 10-Q · filed 2021-11-22 | |
| 2020-12-31 | $9.90M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |